Enzalutamide
- Generic Name
- Enzalutamide
- Brand Names
- Xtandi, Enzalutamide Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16F4N4O2S
- CAS Number
- 915087-33-1
- Unique Ingredient Identifier
- 93T0T9GKNU
- Background
Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012. Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieve...
- Indication
Enzalutamide is indicated for the treatment of castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer (mCRPC). It is also used in combination with talazoparib for the treatment of adult patients with HRR gene-mutated mCRPC.
- Associated Conditions
- Castration Resistant Prostate Cancer, Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Associated Therapies
- -
Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2024-11-25
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Evopoint Biosciences Inc.
- Target Recruit Count
- 307
- Registration Number
- NCT06702995
- Locations
- 🇨🇳
Cancer Hosipital of Shandong First Medical University,440 Jiyan Road, Jinan City, Shandong Province, Jinan, Shandong, China
🇨🇳270 Dongan Road, Shanghai, Shanghai, Shanghai, China
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 675
- Registration Number
- NCT06691984
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer
- Conditions
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2024-10-22
- Target Recruit Count
- 152
- Registration Number
- NCT06652607
- Locations
- 🇮🇹
Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC ONCOLOGIA MEDICA, Roma, Lazio, Italy
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- Conditions
- Interventions
- Other: Genetic testingDrug: Valemetostat TosylateProcedure: Magnetic Resonance ImagingProcedure: Computed TomographyProcedure: Bone scanProcedure: FDG-Positron Emission TomographyProcedure: PSMA PET ScanProcedure: Biospecimen CollectionDrug: CarboplatinDrug: CabazitaxelDrug: Abiraterone AcetateDrug: EnzalutamideDrug: Lutetium Lu 177 Vipivotide Tetraxetan
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 474
- Registration Number
- NCT06632977
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
- Conditions
- Interventions
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 900
- Registration Number
- NCT06629779
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China
🇺🇸AUC Urologists, LLC, Myrtle Beach, South Carolina, United States
🇺🇸Carolina Urologic Research Center, LLC, Myrtle Beach, South Carolina, United States
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT06616155
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Docetaxel and Hormone Treatment Compared to Hormone Treatment Alone in People With Metastatic Castration Sensitive Prostate Cancer and Less Than Optimal PSA Response
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 830
- Registration Number
- NCT06592924
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
- Conditions
- Interventions
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 128
- Registration Number
- NCT06576037
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
- Conditions
- Interventions
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 600
- Registration Number
- NCT06551324
- Locations
- 🇨🇳
Tongji Hospital of Tongji University, Shanghai, Shanghai, China
🇯🇵Keio university hospital, Shinjuku-ku, Tokyo, Japan
🇰🇷Samsung Medical Center, Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT GLOBAL)
- Conditions
- Interventions
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
- Target Recruit Count
- 430
- Registration Number
- NCT06520345
- Locations
- 🇺🇸
Biogenix Molecular LLC, Miami, Florida, United States
🇺🇸XCancer Omaha, Omaha, Nebraska, United States
🇦🇺Westmead Hospital, Sydney, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.